Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

被引：8

作者：

Camidge, D. Ross ^{[1
]}

Gadgeel, Shirish ^{[2
]}

Ou, Sai-Hong ^{[3
]}

Gandhi, Leena ^{[4
]}

Riely, Gregory ^{[5
]}

Cetnar, Jeremy ^{[6
]}

West, Howard ^{[7
]}

Socinski, Mark ^{[8
]}

Chiappori, Alberto ^{[9
]}

Mekhail, Tarek ^{[10
]}

Chao, Bo ^{[11
]}

Borghaei, Hossein ^{[12
]}

Gold, Kathryn ^{[13
]}

Bordogna, Walter ^{[14
]}

Balas, Bogdana ^{[14
]}

Noe, Johannes ^{[14
]}

Golding, Sophie ^{[14
]}

Zeaiter, Ali ^{[14
]}

Shaw, Alice ^{[15
]}

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[3] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[7] Swedish Canc Inst, Seattle, WA USA

[8] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Florida Hosp, Canc Inst, Orlando, FL USA

[11] Ohio State Univ, Columbus, OH 43210 USA

[12] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[13] Univ Texas MD Anderson Canc Ctr, Thorac Med Oncol, Houston, TX 77030 USA

[14] F Hoffmann La Roche, Basel, Switzerland

[15] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

Alectinib; NSCLC; US; ALK-inhibitor;

D O I：

10.1016/j.jtho.2016.11.426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.02

引用

页码：S378 / S378

页数：1

共 50 条

[31] Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
Vavala, Tiziana
Novello, Silvia
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[32] ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
Kim, Edward S.
Barlesi, Fabrice
Mok, Tony
Ahn, Myung-Ju
Shen, Junwu
Zhang, Pingkuan
Ou, Sai-Hong Ignatius
FUTURE ONCOLOGY, 2021, 17 (14) : 1709 - 1719
[33] Safety and efficacy of alectinib versus crizotinib in alk-positive non- small cell lung cancer: An update meta-analysis
Xiong, Rui
Fu, Haitan
Zhang, Qianrui
Li, Wei
PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 36 (02) : 365 - 372
[34] Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Nishio, Makoto
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Tanaka, Tomohiro
Kuriki, Hiroshi
Zeaiter, Ali
Tamura, Tomohide
LUNG CANCER, 2018, 121 : 37 - 40
[35] Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis
Zhu, Viola W.
Lu, Yuxin
Ou, Sai-Hong Ignatius
CLINICAL LUNG CANCER, 2019, 20 (01) : E77 - E80
[36] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
Nishi, Koichi
ANNALS OF ONCOLOGY, 2019, 30
[37] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
Mu, Lifeng
Zhou, Benhong
ADVANCES IN THERAPY, 2020, 37 (02) : 968 - 970
[38] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
Lifeng Mu
Benhong Zhou
Advances in Therapy, 2020, 37 : 968 - 970
[39] Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
Lockney, Natalie A.
Wu, Abraham J.
JOURNAL OF THORACIC DISEASE, 2017, 9 (02) : E152 - E154
[40] ALECTINIB FOR THE TREATMENT OF ALK-POSITIVE STAGE IV NON-SMALL CELL LUNG CANCER
Wong, K. M.
Noonan, S.
O'Bryant, C.
Jimeno, A.
DRUGS OF TODAY, 2015, 51 (03) : 161 - 170

← 1 2 3 4 5 →